InstalabLoading...
InstalabLoading...
Your gut bacteria are not just passive passengers. They actively reshape the bile acids your liver makes, and the byproducts of that work tell a story about whether the gut and liver are in good conversation. Glycolithocholic acid is one of those byproducts, and a stool measurement can hint at digestive inflammation, kidney complications of diabetes, and broader bile acid shifts that standard panels do not capture.
This is a research-stage marker rather than a guideline-driven test. Standardized cutpoints do not exist, so a single number is less useful than a baseline you can track. Still, the patterns showing up in human studies are interesting enough that getting your own reading now gives you a head start as the science matures.
GLCA (glycolithocholic acid) is a secondary bile acid. Your liver makes primary bile acids from cholesterol and sends them into the intestine to help absorb fats. Once there, gut bacteria convert some of them into a molecule called lithocholic acid. Your liver then attaches the amino acid glycine to it, producing GLCA. Because two systems must cooperate to make it, the gut microbes and the liver, GLCA functions as a window into that handoff.
Stool GLCA reflects what is happening in your colon and the bile acid pool that ends up there. Blood and stool measurements are not interchangeable. Studies that measured serum or plasma GLCA capture a different biological fraction, and those findings are noted as such throughout.
The most direct human evidence on stool GLCA comes from ulcerative colitis. In active disease, fecal GLCA drops along with other secondary bile acids, while primary bile acids climb. This pattern tracks with loss of beneficial bacterial groups and higher inflammatory signals in the gut. In one study of fecal samples from people with active ulcerative colitis, GLCA was significantly reduced and showed a negative correlation with calprotectin, a stool marker of intestinal inflammation.
What this means for you: if your stool GLCA is low and you have digestive symptoms, that pattern is worth investigating with a calprotectin test and a conversation with a gastroenterologist about inflammatory bowel disease. Low GLCA on its own does not diagnose colitis, but the combination of low secondary bile acids and elevated calprotectin is a meaningful flag.
Stool GLCA also rises with the progression of kidney disease in people with diabetes. In a study of adults across stages of diabetic kidney disease, fecal GLCA increased step by step alongside worsening kidney function and protein loss in the urine. This is one of the few clinical settings where higher stool GLCA correlates with worse outcomes in a defined population.
If you are managing type 2 diabetes and tracking kidney health, an elevated stool GLCA, alongside a rising urine albumin-to-creatinine ratio or a falling eGFR (a calculated estimate of how well your kidneys filter blood), suggests the gut-bile-acid pathway is shifting in a direction that has been linked to disease progression.
Most liver disease evidence on GLCA comes from serum or plasma, not stool. Studies measuring blood-based GLCA (a related but different measurement) have found it elevated in men with non-alcoholic fatty liver disease, in metabolic dysfunction-associated steatohepatitis (MASH), and in alcohol-associated hepatitis. A meta-analysis of circulating bile acids in metabolic dysfunction-associated steatotic liver disease (MASLD) found GLCA among the bile acids that help distinguish more advanced steatohepatitis from milder disease.
Whether stool GLCA tracks the same way is not directly established. The blood data tell us GLCA is part of the liver disease story; the stool reading is a related but distinct signal that may complement liver enzymes and imaging rather than replace them.
In a nested case-control study of women, higher baseline serum GLCA (not stool) was associated with higher odds of developing colorectal cancer years later. A separate prospective cohort found that prediagnostic plasma levels of certain conjugated bile acids were positively associated with colon cancer risk. These findings come from blood samples, so they suggest the bile acid pathway matters for colon health, but they do not directly establish that high stool GLCA carries the same risk.
GLCA can be either too low or too high depending on context. Low fecal GLCA shows up in active ulcerative colitis, where colon inflammation strips away the bacteria that produce secondary bile acids. High fecal GLCA shows up in diabetic kidney disease, where bile acid handling shifts in a different way. This is not a simple higher-is-worse marker. It is a phenotype indicator, and the meaning depends on what other patterns surround it: gut inflammation, metabolic disease, or kidney function.
There are no standardized clinical reference ranges for stool GLCA. The values reported in research come from specific cohorts using particular lab methods, and they are not directly translatable to your individual result. The numbers below are research-reported orientation, not clinical targets, and your lab will likely report different numbers depending on its assay.
| Context | What Was Reported | What It Suggests |
|---|---|---|
| Healthy controls (research cohorts) | Detectable baseline fecal GLCA alongside other secondary bile acids | A working gut microbiome producing secondary bile acids |
| Active ulcerative colitis | Significantly reduced fecal GLCA, negatively correlated with calprotectin | Loss of secondary-bile-acid-producing bacteria in inflamed gut |
| Diabetic kidney disease | Step-wise increase in fecal GLCA across disease stages | Bile acid shift linked to worsening kidney function |
Source: Yang et al. 2021 (World Journal of Gastroenterology); Sommersberger et al. 2023 (Lipids in Health and Disease); Zhang et al. 2024 (Nutrition and Diabetes). Compare your results within the same lab over time for the most meaningful trend.
Because no consensus cutpoints exist for stool GLCA, a single reading is hard to interpret in isolation. Your own trend over time is more informative. Bile acid metabolites can shift with diet, microbiome changes, and disease progression, so a baseline plus periodic retesting gives you the comparison that matters most.
A reasonable cadence: get a baseline, retest in three to six months if you are making meaningful changes to diet, gut health, or managing a digestive or metabolic condition, then at least annually after that. If you have known inflammatory bowel disease or diabetic kidney disease, more frequent testing aligned with your other monitoring labs makes sense.
An out-of-pattern stool GLCA is a starting point, not a diagnosis. The right next step depends on what surrounds it.
Stool bile acid measurements can be distorted by factors unrelated to your underlying biology. Acute diarrhea changes how much of any bile acid ends up in the sample. Recent antibiotic use can dramatically reduce the bacterial conversion that creates secondary bile acids like GLCA. Inhaled glucocorticoids at high doses have been shown in randomized data to raise plasma glycolithocholate and its sulfated form substantially above baseline; whether the same shift shows up in stool is not established, but it is a reason to be aware of medication effects when interpreting any bile acid result. Sample collection technique and time since last bowel movement also matter for stool tests in general.
Glycolithocholic Acid is best interpreted alongside these tests.